Literature DB >> 22134940

Cheaper, simpler, and better: tips for treating seniors with Parkinson disease.

J Eric Ahlskog1.   

Abstract

Treatment of seniors with Parkinson disease is within the domain of primary care physicians and internists. A good working knowledge of carbidopa/levodopa principles should allow excellent care of most patients, at least during the early years of the disease. Even later, when levodopa responses become more complicated (eg, dyskinesias, motor fluctuations, insomnia, anxiety), levodopa adjustments may be all that is necessary. A dozen tips for optimizing treatment of Parkinson disease are discussed herein.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22134940      PMCID: PMC3228622          DOI: 10.4065/mcp.2011.0443

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  22 in total

1.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.

Authors:  O Rascol; D J Brooks; A D Korczyn; P P De Deyn; C E Clarke; A E Lang
Journal:  N Engl J Med       Date:  2000-05-18       Impact factor: 91.245

2.  Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.

Authors:  J E Ahlskog; M D Muenter
Journal:  Mov Disord       Date:  2001-05       Impact factor: 10.338

3.  Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.

Authors:  R A Hauser; W C Koller; J P Hubble; T Malapira; K Busenbark; C W Olanow
Journal:  Mov Disord       Date:  2000-05       Impact factor: 10.338

4.  L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects.

Authors:  M D Muenter; G M Tyce
Journal:  Mayo Clin Proc       Date:  1971-04       Impact factor: 7.616

Review 5.  Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease.

Authors:  J Eric Ahlskog
Journal:  Mov Disord       Date:  2005-03       Impact factor: 10.338

6.  Levodopa-dyskinesia incidence by age of Parkinson's disease onset.

Authors:  Neeraj Kumar; Jay A Van Gerpen; James H Bower; J Eric Ahlskog
Journal:  Mov Disord       Date:  2005-03       Impact factor: 10.338

7.  Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole.

Authors:  S Frucht; J D Rogers; P E Greene; M F Gordon; S Fahn
Journal:  Neurology       Date:  1999-06-10       Impact factor: 9.910

8.  Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

Authors: 
Journal:  JAMA       Date:  2000-10-18       Impact factor: 56.272

Review 9.  Stages in the development of Parkinson's disease-related pathology.

Authors:  Heiko Braak; Estifanos Ghebremedhin; Udo Rüb; Hansjürgen Bratzke; Kelly Del Tredici
Journal:  Cell Tissue Res       Date:  2004-08-24       Impact factor: 5.249

10.  Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.

Authors:  K C Yeh; T F August; D F Bush; K C Lasseter; D G Musson; S Schwartz; M E Smith; D C Titus
Journal:  Neurology       Date:  1989-11       Impact factor: 9.910

View more
  6 in total

Review 1.  The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's Disease.

Authors:  Gretchen O Reynolds; Michael W Otto; Terry D Ellis; Alice Cronin-Golomb
Journal:  Mov Disord       Date:  2015-12-30       Impact factor: 10.338

2.  Prescription pattern of anti-Parkinson's disease drugs in Japan based on a nationwide medical claims database.

Authors:  Masahiko Suzuki; Masaki Arai; Ayako Hayashi; Mieko Ogino
Journal:  eNeurologicalSci       Date:  2020-07-16

Review 3.  Does PGC1α/FNDC5/BDNF Elicit the Beneficial Effects of Exercise on Neurodegenerative Disorders?

Authors:  Mohammad Jodeiri Farshbaf; Kamran Ghaedi; Timothy L Megraw; Jennifer Curtiss; Mahsa Shirani Faradonbeh; Pooneh Vaziri; Mohammad Hossein Nasr-Esfahani
Journal:  Neuromolecular Med       Date:  2015-11-26       Impact factor: 3.843

Review 4.  Treatment Options for Motor and Non-Motor Symptoms of Parkinson's Disease.

Authors:  Frank C Church
Journal:  Biomolecules       Date:  2021-04-20

Review 5.  Potential Role of Vitamin D in the Elderly to Resist COVID-19 and to Slow Progression of Parkinson's Disease.

Authors:  Casey A Hribar; Peter H Cobbold; Frank C Church
Journal:  Brain Sci       Date:  2020-05-08

6.  Effects of Long-Term Endurance Exercise and Lithium Treatment on Neuroprotective Factors in Hippocampus of Obese Rats.

Authors:  Jusik Park; Wookwang Cheon; Kijin Kim
Journal:  Int J Environ Res Public Health       Date:  2020-05-10       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.